Esperion to Report Fourth Quarter and Full Year 2020 Financial Results February 23, 2021
February 09 2021 - 8:00AM
Esperion (NASDAQ: ESPR), today announced it will report fourth
quarter and full year 2020 financial results after the close of the
U.S. financial markets on Tuesday, February 23, 2021.
Following the release, company management will host a webcast
and conference call at 4:30 p.m. ET to discuss financial results
and business progress. The call can be accessed by dialing (877)
831-3840 (domestic) or (253) 237-1184 (international) five minutes
prior to the start of the call and providing the access code
2689156.
A live audio webcast can be accessed on the investor and media
section of the Esperion website at investor.esperion.com. Access to
the webcast replay will be available approximately two hours after
completion of the call and will be archived on the Company's
website for approximately 90 days.
Esperion Therapeutics
Esperion is The Lipid Management Company. Our team of lipid
experts works to lower bad cholesterol by discovering, developing
and commercializing innovative medicines and combinations with
established medicines. We work hard to make our medicines easy to
take, easy to get and easy to have. We are singularly focused on
disrupting high cholesterol so you can improve your health –
easily. For more information, please
visit www.esperion.com and follow us on Twitter
at www.twitter.com/EsperionInc.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding Esperion's mission
and clinical development and commercialization plan. Any express or
implied statements contained in this press release that are not
statements of historical fact may be deemed to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties that could cause Esperion's actual results to differ
significantly from those projected, including, without limitation,
delays or failures in Esperion’s clinical development and
commercialization plans, or approval of expanded indications, that
existing cash resources may be used more quickly than anticipated,
the impact of COVID-19 on our business, clinical activities and
commercial development plans, and the risks detailed in Esperion's
filings with the Securities and Exchange Commission. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Esperion disclaims any obligation
or undertaking to update or revise any forward-looking statements
contained in this press release, other than to the extent required
by law.
Investor Contact:Kaitlyn
BroscoEsperioncorporateteam@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024